Antibody-Drug Conjugates

Phase 2Small molecule

HHellenic Cooperative Oncology Group

Antibody-Drug Conjugates is one of 37 small molecule programs targeting Alopecia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AlopeciaActive, not recruiting

Breast CancerActive, not recruiting

AlopeciaPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Prolia

Amgen

Preclinical

14 2

DATROWAY

Daiichi Sankyo

Preclinical

4 3

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 4

Lexiscan

Astellas

Preclinical

1 5

Antibody-Drug Conjugates

HHellenic Cooperative Oncology Group

Phase 2

1 6

Chirocaine

PPurdue Pharma LP

Preclinical

1 7

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

3 8

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

1 9

Systemic Treatment

TTaproot Health

Preclinical

1 10

Docetaxel-Carboplatin

NNational University Hospital, Singapore

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

Phase 2Not yet recruiting

Alopecia

NCT07474558

Clinical

Trials by Indication[1]

Alopecia1 trial

SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates

Not yet recruiting·JJules Bordet Institute·Phase 2·NCT07474558·102 enrolled

Safety and Efficacy1 trial

Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan

Completed·HHellenic Cooperative Oncology Group··NCT06504719·312 enrolled

Breast Cancer1 trial

Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer

Completed·SSOLTI Breast Cancer Research Group·Phase 2·NCT02448420·73 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Antibody-Drug Conjugates. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antibody-Drug Conjugates compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antibody-Drug Conjugates. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hellenic Cooperative Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHellenic Cooperative Oncology Group

Antibody-Drug Conjugates

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2031

Trials by Indication[1]

Alopecia1 trial

Safety and Efficacy1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News